immupharma.org Report : Visit Site

Technical data of the immupharma.org

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host immupharma.org. Currently, hosted in Germany and its service provider is 1&1 Internet AG .

the related websites

immupharma.co.uk investing.thisismoney.co.uk iii.co.uk lse.co.uk computershare.com www-uk.computershare.com uk.advfn.com hl.co.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

about us about us corporate strategy our vision and values research & development operations business development awards and grants announcements our team management team scientific team scientific advisory board portfolio our portfolio lupuzor™ auto-immune diseases oncology & ophthalmology metabolism and diabetes investors investor relations aim rule 26 information regulatory news market commentary share price broker research corporate governance board of directors annual reports presentations interviews professional advisers email alerts media events and conferences media room interviews scientific publications contact us lupuzor aiming to deliver a safe treatment for lupus sufferers read more innovative drug development for the benefit of patients worldwide read more aim listed headquarters in london and research centres in france and switzerland read more recent announcements imm september 2018 corporate update september 7, 2018 further analysis from its pivotal phase iii trial of lupuzor™ in patients with systemic lupus erythematosus (sle) shows positive results in the europe cohort 1 may 29, 2018 immupharma plc confident on lupuzor’s™ future april 23, 2018 successful placing to raise £10 million january 24, 2018 pharmaceutical drug development focused on making patient lives better immupharma plc is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. lupuzor ™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing lupus patients in its phase iii pivotal trial. this is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide. we continue to work with our long term partner centre national de la recherche scientifique (cnrs), europe’s largest fundamental research institution and immupharma’s long standing collaboration partner. aim listed developing innovative drugs immupharma plc is a pharmaceutical company listed since 2006 on aim of the london stock exchange (lse:imm), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. immupharma is focused on three therapeutic disease areas – auto-immune (p140) | oncology/ophthalmology | metabolism/diabetes. lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, a life threatening auto immune-disease. lupuzor ™ received ‘gold standard’ approval from the us fda for its phase iii trial with a special protocol assessment and “fast track” designation. the phase iii trial has now been completed. immupharma is led by a commercially focused board and management team with extensive experience. click here for the current corporate update in september 2018. rns announcements more share price loading... market cap 15 minute delayed share price provided by hemscott group limited disclaimer investor relations immupharma transforms care for people worldwide developing innovative drugs for serious medical conditions lead program for the potential breakthrough compound for lupus, the life threatening auto-immune disease immupharma has completed dosing lupus patients in the usa, europe and mauritius in a pivotal phase iii clinical trial of lupuzor ™ with top line results announced. more auto-immune diseases lupuzor ™, is also known by its chemical name ‘ forigerimod’ or p140. immupharma has the potential of expanding the p140 peptide platform into other auto immune conditions such as: rheumatoid arthritis, crohn’s disease, and asthma. very few aim-listed drug development companies have late-stage clinical assets of similar calibre. more oncology & ophthalmology immupharma’s second most advanced pipeline program, ipp-204106 , is a potential treatment for various cancers and acts by modulating angiogenesis (formation of new blood vessels) and proliferation (rapid reproduction). we are also investigating its use in age-related macular degeneration, diabetic retinopathy and other ophthalmological indications. more metabolism and diabetes immupharma’s subsidiary ‘ureka’ has initiated the development of a novel and innovative peptide technology platform through the collaboration with cnrs, gaining access to pioneering research centred on novel peptide drugs at the university of bordeaux and the institut européen de chimie et biologie (iecb). the first therapeutic area being targeted is diabetes. more we are focused on advancing the care of patients suffering from serious medical conditions worldwide. immupharma is aim listed with our headquarters in london and research centres in france and switzerland. to contact us click here aim rule 26 contact information disclaimer privacy policy site map © immupharma plc 2005-2017 | all rights reserved cookies this website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. if you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy i accept

URL analysis for immupharma.org

http://www.immupharma.co.uk/investors/corporate-governance/
http://www.immupharma.co.uk/investors/email-alerts/
http://www.immupharma.co.uk/analysis-pivotal-phase-iii-trial-lupuzor-patients-systemic-lupus-erythematosus-sle-shows-positive-results-europe-cohort1/
http://www.immupharma.co.uk/site-map/
http://www.immupharma.co.uk/news/
http://www.immupharma.co.uk/successful-placing-raise-10-million/
http://www.immupharma.co.uk/about-us/#awards
http://www.immupharma.co.uk/about-us/#vision
http://www.immupharma.co.uk/products/auto-immune-diseases/
http://www.immupharma.co.uk/our-team/#team-fourth-row
http://www.immupharma.co.uk/contact-us/
http://www.immupharma.co.uk/investors/share-price/
http://www.immupharma.co.uk/cookie-policy/
http://www.immupharma.co.uk/disclaimer/
http://www.immupharma.co.uk/our-team/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: IMMUPHARMA.ORG
Registry Domain ID: D138189788-LROR
Registrar WHOIS Server:
Registrar URL: http://registrar.1und1.de
Updated Date: 2017-09-25T19:03:34Z
Creation Date: 2007-01-25T15:48:07Z
Registry Expiry Date: 2018-01-25T15:48:07Z
Registrar Registration Expiration Date:
Registrar: 1&1 Internet SE
Registrar IANA ID: 83
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.6105601459
Reseller:
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Registry Registrant ID: C171986110-LROR
Registrant Name: 1&1 Internet Limited
Registrant Organization: 1&1 Internet Limited
Registrant Street: Discovery House
Registrant Street: 154 Southgate Street
Registrant City: Gloucester
Registrant State/Province: GLS
Registrant Postal Code: GL1 2EX
Registrant Country: GB
Registrant Phone: +44.3333365691
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: [email protected]
Registry Admin ID: C171986110-LROR
Admin Name: 1&1 Internet Limited
Admin Organization: 1&1 Internet Limited
Admin Street: Discovery House
Admin Street: 154 Southgate Street
Admin City: Gloucester
Admin State/Province: GLS
Admin Postal Code: GL1 2EX
Admin Country: GB
Admin Phone: +44.3333365691
Admin Phone Ext:
Admin Fax:
Admin Fax Ext:
Admin Email: [email protected]
Registry Tech ID: C171986110-LROR
Tech Name: 1&1 Internet Limited
Tech Organization: 1&1 Internet Limited
Tech Street: Discovery House
Tech Street: 154 Southgate Street
Tech City: Gloucester
Tech State/Province: GLS
Tech Postal Code: GL1 2EX
Tech Country: GB
Tech Phone: +44.3333365691
Tech Phone Ext:
Tech Fax:
Tech Fax Ext:
Tech Email: [email protected]
Name Server: NS1085.UI-DNS.COM
Name Server: NS1062.UI-DNS.DE
Name Server: NS1089.UI-DNS.BIZ
Name Server: NS1121.UI-DNS.ORG
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of WHOIS database: 2017-10-09T07:28:52Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

Access to Public Interest Registry WHOIS information is provided to assist persons in determining the contents of a domain name registration record in the Public Interest Registry registry database. The data in this record is provided by Public Interest Registry for informational purposes only, and Public Interest Registry does not guarantee its accuracy. This service is intended only for query-based access. You agree that you will use this data only for lawful purposes and that, under no circumstances will you use this data to: (a) allow, enable, or otherwise support the transmission by e-mail, telephone, or facsimile of mass unsolicited, commercial advertising or solicitations to entities other than the data recipient's own existing customers; or (b) enable high volume, automated, electronic processes that send queries or data to the systems of Registry Operator, a Registrar, or Afilias except as reasonably necessary to register domain names or modify existing registrations. All rights reserved. Public Interest Registry reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy.

  REFERRER http://www.pir.org/

  REGISTRAR Public Interest Registry

SERVERS

  SERVER org.whois-servers.net

  ARGS immupharma.org

  PORT 43

  TYPE domain

DOMAIN

  NAME immupharma.org

  HANDLE D138189788-LROR

  CREATED 2007-01-25

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS1085.UI-DNS.COM 217.160.82.85

  NS1062.UI-DNS.DE 217.160.80.62

  NS1089.UI-DNS.BIZ 217.160.81.89

  NS1121.UI-DNS.ORG 217.160.83.121

OWNER

  HANDLE C171986110-LROR

  NAME 1&1 Internet Limited

  ORGANIZATION 1&1 Internet Limited

ADDRESS

STREET
Discovery House
154 Southgate Street

  CITY Gloucester

  STATE GLS

  PCODE GL1 2EX

  COUNTRY GB

  PHONE +44.3333365691

  EMAIL [email protected]

ADMIN

  HANDLE C171986110-LROR

  NAME 1&1 Internet Limited

  ORGANIZATION 1&1 Internet Limited

ADDRESS

STREET
Discovery House
154 Southgate Street

  CITY Gloucester

  STATE GLS

  PCODE GL1 2EX

  COUNTRY GB

  PHONE +44.3333365691

  EMAIL [email protected]

TECH

  HANDLE C171986110-LROR

  NAME 1&1 Internet Limited

  ORGANIZATION 1&1 Internet Limited

ADDRESS

STREET
Discovery House
154 Southgate Street

  CITY Gloucester

  STATE GLS

  PCODE GL1 2EX

  COUNTRY GB

  PHONE +44.3333365691

  EMAIL [email protected]

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .